• Optus Pharmaceutical's Oct. 22, 2026, correction replaced QLOSI's USD 9.77 million regulatory-approval milestone payment with sales-based payments.
• Total milestone payments remain USD 12.22 million under the licensing agreement with Orasis Pharmaceuticals.
• The Korean NDA submission payment falls to USD 2 million from USD 2.45 million.
• Payments of USD 2 million and USD 8.22 million become due at cumulative net sales of USD 40 million and USD 80 million, respectively.
• The NDA submission payment becomes 50% refundable, equivalent to USD 1 million, subject to contractual conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optus Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022900365), on October 22, 2026, and is solely responsible for the information contained therein.